

# Cheryl Burman Award 2026

## PROCESS AND GUIDELINES

### Introduction and background

The Cheryl Burman Award is presented each year at the HNSW Annual General Meeting and Audrey Lamb Community Forum. It celebrates a person, group or service whose work has made a real difference in the lives of people and communities affected by viral hepatitis in NSW, through care, support, information, prevention or treatment.

The award is named in honour of Cheryl Burman, whose leadership, commitment and care helped shape the early response to viral hepatitis in NSW. Cheryl served on the Board of the Hepatitis C Council of NSW from 1993 to 2000, including as President from 1995 to 1999, and made a lasting contribution to the leadership and governance of Hepatitis NSW.

### Eligibility

The Cheryl Burman Award recognises achievements during the 2025-26 financial year, while also valuing the longer-term contribution nominees make to supporting people and communities affected by viral hepatitis. To be eligible, nominations must meet the following guidelines:

- Individuals, groups and services are all welcome to be nominated.
- Current Hepatitis NSW Board members and staff on ongoing or fixed-term contracts are not eligible.
- Nominees must be actively contributing to the elimination of viral hepatitis in NSW.

- Self-nominations are not accepted.
- The work being recognised must have taken place in NSW.
- Previous nominees and past award recipients may be nominated again in future years.



## Selection

The award recipient is selected by the Hepatitis NSW Board of Governance, based on recommendations from a Board sub-committee that reviews and shortlists nominations. In making their decision, the Board looks for work that has made a clear, meaningful and positive difference for people and communities affected by viral hepatitis in NSW. Strong nominations will usually show excellence in one or more of the following areas:

- Strong community involvement or a significant contribution to improving the lives and wellbeing of people living with viral hepatitis.
- An evidence-based health promotion project that helps prevent transmission of viral hepatitis and supports community awareness.
- Innovative clinical services that make care easier to access and improve health outcomes.
- Research, or the start of research, that strengthens prevention, treatment, care or elimination efforts.

The Board will also consider:

- Evidence of creativity, leadership and care in the way the work was carried out.
- A clear demonstration of initiative and innovation.
- Whether the achievement was led by an individual or made possible through strong collaboration.
- How the work has helped build stronger relationships across the sector.
- How the work has helped reduce viral hepatitis and improve testing, health management, liver health assessment, treatment, research, or access to services for priority populations, including:
  - people in NSW living with, or at risk of, hepatitis B or hepatitis C;
  - people in custodial settings living with, or at risk of, viral hepatitis;
  - people who inject drugs, or may be likely to inject drugs;
  - people from culturally and linguistically diverse backgrounds living with, or at risk of, viral hepatitis;
  - First Nations people living with, or at risk of, viral hepatitis;
  - children born to mothers with chronic viral hepatitis; and
  - young people living with, or at risk of, viral hepatitis.